Abstract
Background
Resistance to thyroid hormone (RTH) is a syndrome characterized by refractoriness of the pituitary and/or peripheral tissues to the action of thyroid hormone. Mutations in the thyroid hormone receptor β (TRβ) gene result in TRβl mutants that mediate the clinical phenotype by interfering with transcription of thyroid hormone-regulated genes via a dominant negative effect. In this study, we developed transgenic mice harboring PV, a potent dominant negative human mutant TRβl devoid of thyroid hormone binding and transcriptional activation, as an animal model to understand the molecular basis of this human disease.
Materials and Methods
Standard molecular biology approaches were used to obtain a cDNA fragment containing mutant PV which was injected into the pronucleus of fertilized egg. Founders were identified by Southern analysis and the expression of PV in tissues was determined by RNA and immunohistochemistry. Thyroid function was determined by radioimmunoassays of the hormones and the behavior of mice was observed using standard methods.
Results
The expression of mutant PV was directed by the β-actin promoter. Mutant PV mRNA was detected in all tissues of transgenic mice, but the levels varied with tissues and with different lines of founders. Thyroid function tests in transgenic mice with high expression of mutant PV showed a significantly (∼1.5-fold) higher mean serum total of L-thyroxine levels (p < 0.01) than those of nontransgenic mice. Moreover, thyroid-stimulating hormone levels were not significantly different from those of nontransgenic mice. In addition, these mice displayed decreased weights and a behavioral phenotype characterized by hyperactivity.
Conclusions
These mice have phenotypic features consistent with the commonly observed clinical features of RTH and could be used as a model system to better understand the action of mutant TRβl in a physiological context, which could lead to better treatment for this disease.
Similar content being viewed by others
References
Cheng S-y (1995) New insights into the structure and function of the thyroid hormone receptor. J. Biomed. Sei. 2: 77–89.
Oppenheimer JH, Schwartz HL, Strait KA (1994) Thyroid hormone action 1994: The plot thickens. Eur. J. Endocrinol. 130: 15–24.
Yap N, Yu C-L, Cheng S-y (1996) Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53. Proc. Natl. Acad. Sei. U.S.A. 93: 4273–4277.
Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L (1996) Nuclear receptor coactivators and corepressors. Mol. Endocrinol. 10: 1167–1177.
Refetoff S, Weiss RE, Usala SJ (1993) The syndromes of resistance to thyroid hormone. Endocr. Rev. 14: 348–399.
Usala SJ (1995) New developments in clinical and genetic aspects of thyroid hormone resistance syndromes. The Endocrinologist 5: 68–76.
Refetoff S, DeWind LT, DeGroot LJ (1967) Familial syndrome combining deaf mutism, stippled epiphyses, goiter, and abnormally high PBI: Possible target organ refractoriness to thyroid hormone. J. Clin. Endocrinol. Metab. 27: 279–294.
Brucker-Davis F, Skarulis MC, Grace MB, Benichou J, Hauser P, Wiggs E, Weintraub BD (1995) Genetic and clinical features of 42 kindreds with resistance to thyroid hormone: The NIH prospective study. Ann. Intern. Med. 123: 572–583.
Yen PM, Chin WW (1994) Molecular mechanisms of dominant negative activity by nuclear hormone receptors. Mol. Endocrinol. 8: 1450–1454.
Hayashi Y, Mangoura D, Refetoff S (1996) A mouse model of resistance to thyroid hormone produced by somatic gene transfer of a mutant thyroid hormone receptor. Mol. Endocrinol. 10: 100–106.
Barlow C, Meister B, Lardelli M, Lendahl U, Vennstrom B (1994) Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erbA. EMBO J. 13: 4241–4250.
Sap J, Munoz A, Damm K, Goldberg Y, Ghysdael J, Leutz A, Beug H, Vennstrom B (1986) The c-erbA protein is a high affinity receptor for thyroid hormone. Nature 324: 635–640.
Weinberger C, Thompson CC, Ong ES, Lebo R, Gruol DJ, Evans RM (1986) The c-erbA gene encodes a thyroid hormone receptor. Nature 324: 641–646.
Forrest D, Hanebuth E, Smeyne RJ, Everds N, Stewart CL, Wehner JM, Curran T (1996) Recessive inheritance to thyroid hormone in mice lacking thyroid hormone receptor β: Evidence for tissue-specific modulation of receptor function. EMBO J. 15: 3006–3015.
Takeda K, Sakurai A, DeGroot LJ, Refetoff S (1992) Recessive inheritance of thyroid horone resistance caused by complete deletion of the protein-coding region of the thyroid hormone reeeptor-β gene. J. Clin. Endocrinol. Metab. 74: 49–55.
Ray P, Higgins KM, Tan JC, Chu TY, Yee NS, Nguyen H, Lacy E, Besmer P (1991) Ectopic expression of a c-kitW42 minigene in transgenic mice: Recapitulation of W phenotypes and evidence for c-kit function in melano-blast progenitors. Genes Dev. 5: 2265–2273.
Gunning P, Leavitt J, Muscat G, Ng S-Y, Kedes L (1987) A human beta-actin expression vector system directs high-level accumulation of antisense transcripts. Proc. Natl Acad. Sei. U.S.A. 84: 4831–4835.
Parrilla RA, Mixson AJ, McPherson JA, Mc-Claskey JH, Weintraub BD (1991) Characterization of seven novel mutations of the c-erbAβ gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two “hot spot” regions of the ligand binding domain. J. Clin. Invest. 88: 2123–2130.
Meier CA, Dickstein BM, Ashizawa K, Mc-Claskey JH, Muchmore P, Ransom SC, Menke JB, Hao E-H, Usala SJ, Bereu BB, Cheng S-y, Weintraub BD (1992) Variable transcriptional activity and ligand binding of mutant beta-1 3,5,3′-triiodothyronine receptors from four families with generalized resistance to thyroid hormone. Mol. Endocrinol. 6: 248–258.
Hogan B, Lacy E (1986) Manipulating the Mouse Embryo. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
Bhat MK, McPhie P, Ting Y-T, Zhu X-G, Cheng S-y (1995) Structure of the carboxy-terminal region of thyroid hormone nuclear receptor and its possible role in hormone-dependent intermolecular interactions. Biochemistry 34: 10591–10599.
Hasumura S, Kitagawa S, Lovelace E, Willingham MC, Pastan I, Cheng S-y (1986) Characterization of a membrane-associated 3,3′,5-triiodo-L-thyronine binding protein by use of monoclonal antibodies. Biochemistry 25: 7881–7888.
Fitzgerald RE, Berres M, Schaeppi U (1988) Validation of a photobeam system for assessment of motor activity in rats. Toxicology 49: 433–439.
Zametkin AJ, Rapoport JL (1987) Neurobiology of attention-deficit disorder with hyperactivity: Where have we come in 50 years? J. Am. Acad. Child. Adolesc. Psychiatry 26: 676–686 [Erratum, (1988) 27: 338].
Hauser P, Zametkin AJ, Martinez B, Vitiello B, Matochik JA, Mixson AJ, Weintraub BD (1993) Attention deficit-hyperactivity disorder in people with generalized resistance to thyroid hormone. N. Engl. J. Med. 328: 997–1001.
Shenker A (1992) The mechanism of action of drugs used to treat attention-deficit hyperactivity disorder: Focus on catecholamine receptor pharmacology. Adv. Pediatr. 39: 337–382.
Malone MA, Kershner JR, Swanson JM (1994) Hemispheric processing and methylphenidate effects in attention-deficit hyperactivity disorder. J. Child Neurol. 9: 181–189.
Shaywitz BA, Teicher MH, Cohen DJ, Anderson GM, Young JG, Levitt P (1984) Dopaminergic but not adrenergic mediation of hyperactivity and performance deficits in the developing rat pup. Psychopharmacology 82: 73–77.
Xu M, Hu X-T, Cooper DC, Moratalla R, Graybiel AM, White FJ, Tonegawa S (1994) Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysio-logical effects in dopamine Dl receptor mutant mice. Cell 79: 945–955.
Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park B-H, Gauda EB, Lee EJ, Cool MH, Sibley DR, Gerfen CR, Westphal H, Fuchs S (1996) A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Natl Acad. Sei. U.S.A. 93: 1945–1949.
Archer T, Danysz W, Fredriksson A, Jonsson G, Luthman J, Sundstrom E, Teiling A (1988) Neonatal 6-hydroxydopamine-in-duced dopamine depletions: Motor activity and performance in maze learning. Pharmacol. Biochem. Behav. 31: 357–364.
Power RF, Mani SK, Codina J, Conneely OM, O’Malley BW (1991) Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 254: 1636–1639.
Crocker AD, Overstreet DH (1984) Modification of the behavioral effects of haloperi-dol and of dopamine receptor regulation by altered thyroid status. Psychopharmacology 82: 102–106.
Strait KA, Schwartz HL, Perez-Castillo A, Oppenheimer JH (1990) Relationship of c-erbA mRNA content to tissue triiodothyronine nuclear binding capacity and function in developing and adult rats. J. Biol Chem. 265: 10514–10521.
Acknowledgments
We thank Yetem Eshete for expert care of the mice and assistance with various mouse rodent procedures, Michael Smith, M.D. (Department of Pathology and Laboratory Medicine, Medical University of South Carolina), for advice in the interpretation of the neuronal distribution of reactive nuclei in sections of mouse brain, Philip Skolnick, Ph.D., for helpful discussions regarding the behavioral phenotype of our mice, William Wood, Ph.D., and Virginia Sarapura, M.D., for the mouse TRβl plasmid, Fredric Wondisford, M.D., Christoph Meier, M.D., Peter Hauser, M.D., and John Matochik, Ph.D., for helpful discussions, Mark Pineda for technical assistance and Mathis Grossmann, M.D., Simeon Taylor, M.D., and Françoise Davis, M.D., for critical review of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicated by I. Pastan.
Rights and permissions
About this article
Cite this article
Wong, R., Vasilyev, V.V., Ting, YT. et al. Transgenic Mice Bearing a Human Mutant Thyroid Hormone βl Receptor Manifest Thyroid Function Anomalies, Weight Reduction, and Hyperactivity. Mol Med 3, 303–314 (1997). https://doi.org/10.1007/BF03401809
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03401809